Details of the Drug

General Information of Drug (ID: DM704AN)

Drug Name
Sapacitabine
Synonyms CYC682
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Phase 3 [1]
Acute myeloid leukaemia 2A60 Phase 3 [2]
Breast cancer 2C60-2C65 Phase 2 [3]
Myelodysplastic syndrome 2A37 Phase 2 [1]
Ovarian cancer 2C73 Phase 2 [3]
Pancreatic cancer 2C10 Phase 2 [3]
⏷ Show the Full List of Indication(s)
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
Chemical Identifiers
Formula
C26H42N4O5
Canonical SMILES
CCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)C2C(C(C(O2)CO)O)C#N
InChI
1S/C26H42N4O5/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-23(32)28-22-16-17-30(26(34)29-22)25-20(18-27)24(33)21(19-31)35-25/h16-17,20-21,24-25,31,33H,2-15,19H2,1H3,(H,28,29,32,34)/t20-,21+,24-,25+/m0/s1
InChIKey
LBGFKUUHOPIEMA-PEARBKPGSA-N
Cross-matching ID
PubChem CID
153970
ChEBI ID
CHEBI:145429
CAS Number
151823-14-2
UNII
W335P73C3L
DrugBank ID
DB06365
TTD ID
D0D4RF
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT01303796) A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)